Protein

Image: iStock/Pilin_Petunyia

AstraZeneca sets out on a $1bn 'Bicycle' path

By Dan Stanton

AstraZeneca has partnered with Bicycle Therapeutics in a potential $1bn deal to develop a new class of small molecules which have antibody-like properties.